Table 1.
Baseline patient characteristics of patient with metastatic urothelial cancer at the start of pemetrexed treatment.
| Historic Cohort | NCT02693717 | Total cohort | |||
|---|---|---|---|---|---|
| MTAPdef | MTAPprof | MTAPdef | |||
| Patient Characteristics | N (%) | N (%) | N (%) | N (%) | |
| All | 4 (100%) | 10 (100%) | 7 (100%) | 21 (100%) | |
| Age - median (min, max) | 65 (57, 80) | 69 (49, 79) | 71 (68, 80) | 70 (49, 80) | |
| Gender | F | 2 (50%) | 2 (20%) | 4 (57%) | 8 (38%) |
| M | 2 (50%) | 8 (80%) | 3 (43%) | 13 (62%) | |
| Race | Asian | 1 (25%) | 3 (30%) | 0 (0%) | 4 (19%) |
| Black | 0 (0%) | 0 (0%) | 3 (43%) | 3 (14%) | |
| Latino/Hispanic | 1 (25%) | 0 (0%) | 0 (0%) | 1 (5%) | |
| White | 2 (50%) | 7 (70%) | 4 (57%) | 13 (62%) | |
| ECOG PS | 0 | 1 (25%) | 6 (60%) | 3 (43%) | 10 (48%) |
| 1 | 2 (50%) | 3 (30%) | 4 (57%) | 9 (43%) | |
| 2 | 1 (25%) | 1 (10%) | 0 (0%) | 2 (9%) | |
| Sites of metastasis | Nodal only | 1 (25%) | 6 (60%) | 3 (43%) | 10 (48%) |
| Visceral (lung, bone, liver, or others) | 3 (75%) | 4 (40%) | 4 (57%) | 11 (52%) | |
| Prior Therapy | Gem/Cis | 2 (50%) | 7 (70%) | 3 (43%) | 12 (57%) |
| Immune checkpoint therapy | 0 (0%) | 1 (10%) | 5 (71%) | 6 (28%) | |
| GTA | 0 (0%) | 2 (20%) | 2 (29%) | 4 (19%) | |
| MVACa | 0 (0%) | 5 (50%) | 1 (14%) | 6 (28%) | |
| CGI | 1 (25%) | 1 (10%) | 1 (14%) | 3 (14%) | |
| IAGEM | 0 (0%) | 1 (10%) | 0 (0%) | 1 (5%) | |
| Other Prior Therapyb | 1 (25%) | 2 (20%) | 1 (14%) | 4 (19%) | |
| Number of Prior Regimens | 1 | 4 (100%) | 4 (40%) | 3 (43%) | 11 (53%) |
| 2 | 0 (0%) | 3 (30%) | 1 (14%) | 4 (19%) | |
| 3 | 0 (0%) | 3 (30%) | 3 (43%) | 6 (28%) | |
aOne MTAPprof retrospective patient with MVAC as metastatic therapy was included. All other MVAC therapy was adjuvant or neo-adjuvant therapy.
bOther prior therapies include Gemcitabine and Cyclophosphamide (n = 1), carboplatin and paclitaxel (n = 2), and paclitaxel (n = 1).
MTAPdef MTAP deficient, MTAPprof MTAP proficient, ECOG PS Eastern Cooperative Oncology Group performance status, Gem/cis gemcitabine/cisplatin, GTA gemcitabine, taxotere, and adriamycin, MVAC methotrexate, vinblastine, adriamycin, and cisplatin, CGI cisplatin, gemcitabine, and ifosfamide, IAGEM ifosfamide, adriamycin, and gemcitabine.